II. Definitions
III. Epidemiology
- Incidence: 10 cases per 100,000
- Children comprise 50% of ITP cases (primarily acute ITP)
- Most common isolated Thrombocytopenia cause in children
- Peak onset between ages 2 to 4 years
- Primary ITP
- Incidence: 3.3 per 100,000
- Prevalence: 9.5 per 100,000
IV. Pathophysiology
- IgG Antibody develops against Platelet membrane Antigen
- Acute Idiopathic Thrombocytopenic Purpura
- Immune complex formation and complement deposition on Platelets as a Hypersensitivity Reaction
- Acute onset follows Viral Exanthem or Viral Infection
- Occurs in otherwise healthy patients and typically children of either gender
- Chronic Idiopathic Thrombocytopenic Purpura
- Automimmune reaction with autoantibody formation, Platelet sensitization and premature removal from circulation
- Insidious onset in patient with immune disorder
- More common onset in teenage girls and women
- Rarely resolves spontaneously and associated with higher complication rates
V. Causes: Secondary Immune Thrombocytopenic Purpura
-
Lymphoproliferative Disorders or Myelodysplastic Syndrome
- Evaluate in all patients over age 60 years with Immune Thrombocytopenic Purpura
- Systemic Lupus Erythematosus
- Antiphospholipid Syndrome
- Graves Disease
- Sarcoidosis
- HIV Infection
- Epstein-Barr Virus Infection (EBV or mononucleosus)
- Cytomegalovirus (CMV)
- Varicella-Zoster Virus
- Hepatitis C Virus
VI. Findings: Signs and Symptoms
- Preceding Viral Infection is common in children
- Mild symptoms (often asymptomatic)
- Petechiae
- Non-palpable Purpura
- Mild Splenomegaly in 5 to 10% of cases
- Significant Splenomegaly suggests alternative cause other than primary ITP
- Bleeding complications
- May present with mild mucosal bleeding
- Significant bleeding associated with severe Thrombocytopenia (Platelet Count <20k per uL)
- Absent signs
- No fever, lethargy, pallor or weight loss
- No bone or Joint Pain
- No Lymphadenopathy
- No Hepatomegaly
VII. Labs
- See Thrombocytopenia
- No specific test defines Immune Thrombocytopenic Purpura (diagnosis of exclusion)
- Exclude other Thrombocytopenia Causes first
-
Complete Blood Count with Platelets
- Other than Thrombocytopenia, remainder of blood count is typically normal
- Platelet Count
- Acute, rapid drop in Platelet Count
- Platelet Count is typically 50k to 100k
- May decrease to levels at risk for life threatening bleeding (<10k/uL)
VIII. Differential Diagnosis
- See Thrombocytopenia
- See Purpura
- ITP is uncommon in pregnancy (<0.1%), but consider alternative diagnoses in pregnancy
IX. Management: General
- See Thrombocytopenia for hospitalization criteria
- Hematology Referral best within first 72 hours of diagnosis
- Outpatient Management Indications (most patients)
- Platelet Count >20k/uL AND
- Minimal to no bleeding AND
- Otherwise asymptomatic
- Emergent management
- Indications for urgent or emergent management (uncommon)
- Platelet Count <10,000/uL
- Serious Hemorrhage
- Urgent or emergent surgery required
- Platelet Transfusion
- Platelet Transfusion at dosing 2-3 fold greater than usual dose
- Platelet survival increases with IgG infusion immediately after Platelet Transfusion
- Indications for urgent or emergent management (uncommon)
X. Management: Hematology
- First-Line
- Corticosteroids
- Indicated for severe Thrombocytopenia
- Typically indicated with Platelet Count <30,000 per uL
- Platelets increase within a week of starting Corticosteroids
- Dosing
- Methylprednisolone 30 ml/kg/day over 20-30 min up to 1 g/day IV OR
- Prednisone 1-1.5 mg/kg orally daily
- Low dose in children with acute ITP with non-life threatening mucosal bleeding needing treatment
- Consider short-course of Corticosteroids (<7 days)
- Indicated for severe Thrombocytopenia
- Intravenous Immune globulin (IV IG)
- Dose: 1 g/kg/day for 2-3 days
- Rituximab (Rituxan)
- Corticosteroids
- Refractory cases
- Anti-D Immune globulin
- May be used in Rh Positive patients
- May be considered as alternative to Corticosteroids
- Thrombopoietin receptor Agonist
- Splenectomy
- Indicated if ITP >1 year and corticosterioids and Immunoglobulin Are ineffective at maintaining adequate Platelet Counts
- Safe and effective (however subjects patient to lifelong Asplenia risk)
- May be preferred in younger patients
- Gadenstatter (2002) Am J Surg 184:606-10 [PubMed]
- Anti-D Immune globulin
XI. Complications
-
Intracranial Hemorrhage (ICH)
- Children: 0.5%
- Adults: 1.5%
- Severe non-ICH Bleeding
- Children: 3-20%
- Adults: 10%
XII. Prognosis
- Children: Acute Idiopathic Thrombocytopenic Purpura
- Less severe in children
- Recovery within 6 to 12 months for 80-90% of children
- Most cases resolve within weeks
- Adults
- More chronic, insidious course than for adults
- High complication rates
XIII. References
- Merrill and Gillen (2016) Crit Dec Emerg Med 30(3): 3-8
- Blanchette (2000) Semin Hematol 37(3):299-314 [PubMed]
- Bolton-Maggs (2000) Arch Dis Child 83(3):220-2 [PubMed]
- Gauer (2022) Am Fam Physician 106(3): 288-98 [PubMed]
- Gauer (2012) Am Fam Physician 85(6): 612-22 [PubMed]
- George (1996) Blood 88:3-40 [PubMed]
- Jones (2024) Am Fam Physician 110(1): 58-64 [PubMed]
- Neunert (2019) Blood Adv 3(23): 3829-66 [PubMed]
- Souid (1995) Clin Pediatr 34:487-94 [PubMed]